Preeclampsia association of placental nucleotide variations in eNOS, VEGFA, and FLT-1 genes in Latin American pregnant women.

INTRODUCTION: Preeclampsia is a leading cause of maternal and fetal morbidity in low- and middle-income countries, including those in Latin America. Placental vascular alterations are crucial in the pathophysiology of preeclampsia and few studies have evaluated nucleotide variations on genes associated with vascular regulation in the human placenta. This study aimed to evaluate whether placental nucleotide variations on eNOS, VEGFA, and FLT-1 genes are more frequently associated with preeclampsia in the Latin American population. METHODS: This case-control study included placental tissue from 88 controls and 82 cases that were genotyped through Taqman probes for eNOS, VEGFA, and FLT-1 genes. The intergroup comparisons were analyzed with the Mann-Whitney U test. Genotype and allele frequencies were compared by the X2 test. The association between the nucleotide variants with preeclampsia was evaluated through logistic regression analysis. RESULTS: A significant association was observed for VEGFA SNV rs2010963 (OR 1.95; CI 95% 1.13-3.37), after adjusting for population substructure. The allele combination T, G, G, C, C, C (rs2070744, rs1799983, rs2010963, rs3025039, rs699947 and rs4769613 respectively), showed a negative association with preeclampsia (OR 0.08; CI 95% 0.01-0.93). DISCUSSION: Placental SNV rs2010963 in the VEGFA gene was a risk factor for preeclampsia, while the allele combination T, G, G, C, C, C may represent potential protective factors for preeclampsia within Latin American women.

Frontotemporal dementia presentation in patients with heterozygous p.H157Y variant of TREM2.

BACKGROUND: The triggering receptor expressed on myeloid cell 2 (TREM2) is a major regulator of neuroinflammatory processes in neurodegeneration. To date, the p.H157Y variant of TREM2 has been reported only in patients with Alzheimer's disease. Here, we report three patients with frontotemporal dementia (FTD) from three unrelated families with heterozygous p.H157Y variant of TREM2: two patients from Colombian families (study 1) and a third Mexican origin case from the USA (study 2). METHODS: To determine if the p.H157Y variant might be associated with a specific FTD presentation, we compared in each study the cases with age-matched, sex-matched and education-matched groups-a healthy control group (HC) and a group with FTD with neither TREM2 mutations nor family antecedents (Ng-FTD and Ng-FTD-MND). RESULTS: The two Colombian cases presented with early behavioural changes, greater impairments in general cognition and executive function compared with both HC and Ng-FTD groups. These patients also exhibited brain atrophy in areas characteristic of FTD. Furthermore, TREM2 cases showed increased atrophy compared with Ng-FTD in frontal, temporal, parietal, precuneus, basal ganglia, parahippocampal/hippocampal and cerebellar regions. The Mexican case presented with FTD and motor neuron disease (MND), showing grey matter reduction in basal ganglia and thalamus, and extensive TDP-43 type B pathology. CONCLUSION: In all TREM2 cases, multiple atrophy peaks overlapped with the maximum peaks of TREM2 gene expression in crucial brain regions including frontal, temporal, thalamic and basal ganglia areas. These results provide the first report of an FTD presentation potentially associated with the p.H157Y variant with exacerbated neurocognitive impairments.

Variants in the Sequence of the Probe Hybridization Site May Affect MLPA Performance in Patients with Duchenne/Becker Muscular Dystrophy.

BACKGROUND: The MLPA (multiplex ligation dependent probe amplification) technique is currently the test most widely used to detect mutations in the Duchenne/Becker muscular dystrophy (DMD) gene in the initial assessment. However, several studies have suggested that MLPA results require implementing other detection methods due to false duplication. Our aim was to evaluate variables that could alter the peak ratio in MLPA in individuals with Duchenne/Becker muscular dystrophy (DMD/BMD) who present sequence variants at the probe hybridization site, such as the location of sequence variants (SVs), melting temperature of the probe, and the type of variant. METHODS: We analyzed patients with clinical suspicion of DMD/BMD through the MLPA technique. The DMD gene was sequenced in patients with normal results in MLPA. RESULTS: Of 111 patients, 72 had an abnormal MLPA result, of which 10 had a single exon abnormal peak, and 39 had a normal peak ratio. Out of 10 patients, 4 (40%) with a single exon abnormal peak ratio had SV at the hybridization site of the probe. In the other 6, the deletion was confirmed. Out of 39 patients with a normal peak ratio, 11 presented SVs at the hybridization site of the probe, and DMD/BMD was confirmed. CONCLUSIONS: In cases of abnormal peak ratio results of MLPA in a single exon, it would be valuable to sequence the DMD gene to assess whether variants in the probe hybridization site might result in a false positive that could be interpreted as an exon deletion.

Association between risk polymorphisms for neurodegenerative diseases and cognition in colombian patients with frontotemporal dementia.

Frontotemporal dementia (FTD) is a heterogeneous neurodegenerative disease of presenile onset. A better characterization of neurodegenerative disorders has been sought by using tools such as genome-wide association studies (GWAS), where associations between single nucleotide polymorphisms (SNPs) and cognitive profiles could constitute predictive biomarkers for these diseases. However, in FTD, associations between genotypes and cognitive phenotypes are yet to be explored. Here, we evaluate a possible relationship between genetic variants and some cognitive functions in an FTD population. Methodology: A total of 47 SNPs in genes associated with neurodegenerative diseases were evaluated using the Sequenom MassARRAY platform along with their possible relationship with performance in neuropsychological tests in 105 Colombian patients diagnosed with FTD. Results and discussion: The SNPs rs429358 (APOE), rs1768208 (MOBP), and rs1411478 (STX6), were identified as risk factors for having a low cognitive performance in inhibitory control and phonological verbal fluency. Although the significance level was not enough to reach the corrected alpha for multiple comparison correction, our exploratory data may constitute a starting point for future studies of these SNPs and their relationship with cognitive performance in patients with a probable diagnosis of FTD. Further studies with an expansion of the sample size and a long-term design could help to explore the predictive nature of the potential associations we identified.

Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Pregnancy. A Non-systematic Review of Clinical Presentation, Potential Effects of Physiological Adaptations in Pregnancy, and Placental Vascular Alterations.

In December 2019, the novel Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) rapidly spread to become a pandemic. To date, increasing evidence has described the potential negative impact of SARS-CoV-2 infection on pregnant women. Although the pathophysiology of coronavirus disease 2019 (COVID-19) is not entirely understood, there is emerging evidence that it causes a severe systemic inflammatory response associated with vascular alterations that could be of special interest considering some physiological changes in pregnancy. Additionally, these alterations may affect the physiology of the placenta and are associated with pregnancy complications and abnormal histologic findings. On the other hand, data about the vaccine against SARS-CoV-2 are limited, but the risks of administering COVID-19 vaccines during pregnancy appear to be minimal. This review summarizes the current literature on SARSCoV2 virus infection, the development of COVID-19 and its relationship with physiological changes, and angiotensin-converting enzyme 2 (ACE2) function during pregnancy. We have particularly emphasized evidence coming from Latin American countries.

Assessment of Placental Extracellular Vesicles-Associated Fas Ligand and TNF-Related Apoptosis-Inducing Ligand in Pregnancies Complicated by Early and Late Onset Preeclampsia.

Preeclampsia (PE) is a hypertensive disorder that affects 2-8% of pregnancies and is one of the main causes of fetal, neonatal, and maternal mortality and morbidity worldwide. Although PE etiology and pathophysiology remain unknown, there is evidence that the hyperactivation of maternal immunity cells against placental cells triggers trophoblast cell apoptosis and death. It has also been reported that placenta-derived extracellular vesicles (EV) carry Fas ligand (FasL) and Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and trigger apoptosis in Jurkat T cells. This study aimed to quantify and compare FasL and TRAIL expression in EV derived from cultures of placenta explants from women with PE (early versus late) and women with uncomplicated pregnancies. Also, the study assessed EV capacity to induce apoptosis in Jurkat T cells. The authors isolated EV from placenta explant cultures, quantified FasL and TRAIL using ELISA, and analyzed EV apoptosis-inducing capability by flow cytometry. Results showed increased FasL and TRAIL in EV derived from placenta of women with PE, and increased EV apoptosis-inducing capability in Jurkat T cells. These results offer supporting evidence that EV FasL and TRAIL play a role in the pathophysiology of PE.

Expression of tissue factor and thrombomodulin in the placentas of pregnancies affected by early-onset and late-onset preeclampsia.

AIM: To analyze the differential genetic expression and protein localization of thrombomodulin (THBD) and tissue factor (F3) in the placentas of pregnancies affected by preeclampsia. METHODS: We assessed the expression of THBD and F3 by immunohistochemistry and real-time polymerase chain reaction (PCR) in placentas from 20 PE cases: 10 early-onset PE placentas, 10 late-onset PE placentas, and 10 control cases (normal pregnancies). RESULTS: In cases, we found higher THBD and F3 RNA levels in placental tissue. Protein expression in controls differed from that in late-onset PE placentas, which had lower THBD levels in syncytiotrophoblasts and amniotic cells. Likewise, late-onset PE placentas exhibited comparatively lower F3 expression in the perivillous fibrin. In contrast, early-onset PE had high F3 expression in the subdecidual fibrin. We found no significant differences in the F3/THBD ratio between the groups. CONCLUSION: Our study supports evidence that shows the involvement of F3 and THBD in placental disorders. Furthermore, this finding contributes to a better understanding of the physio-pathological role that these molecules may play in the development of this heterogeneous disease.

Protein and genetic expression of CDKN1C and IGF2 and clinical features related to human umbilical cord length.

BACKGROUND: Umbilical cord (UC) abnormalities are related to neurological outcome and death; specific molecular factors that might be involved are, as yet, unknown; however, protein-coding genes insulin-like growth factor 2 (IGF2) and cyclin-dependent kinase inhibitor 1C (CDKN1C) have been identified as potential candidates. METHODS: An analytical observational study was carried out. Newborn UCs were collected, along with their clinical and morphological features. Immunohistochemical analysis was made on paraffin-embedded sections and quantitative reverse transcription polymerase chain reaction (qRT-PCR) was performed in fresh UC tissue for the assessment of gene expression. RESULTS: A total of 100 newborns were included. A significant association was found between long UC and prematurity [odds ratio (OR) 9] and long UC and respiratory distress (OR 4.04). Gestational diabetes (OR 8.55) and hypertensive disorders of pregnancy (HDP) (OR 4.71) were found to be related to short UCs. The frequency for abnormal UC length was higher than expected. UC length was positively correlated with maternal, newborn and placental weight. No statistical association was found between IGF2 and CDKN1C (p57) expression and UC length; however, there was a tendency for higher CDKN1C expression in short UCs, while, on the contrary, higher IGF2 expression for long UCs. CONCLUSION: UC length was observed to be associated with maternal and newborn complications. Protein expression, messenger RNA (mRNA) activity and the activity of said genes seem to be related to UC length.

Risk factors and fetal outcomes for preeclampsia in a Colombian cohort.

In Latin America and the Caribbean, hypertensive pregnancy disorders are responsible for almost 26% of all maternal deaths [1] and, in Colombia, they account for 59% of all severe maternal morbidity (SMM) cases, and 59.7% of all SMM cases in adolescents [2]. One of the most important hypertensive pregnancy disorders is preeclampsia (PE). Lives can be saved, if PE is prevented, or detected early and properly managed. Prevention and detection depend on identifying the risk factors associated with PE, and, as these have been shown vary by population, they should be determined on a population-by-population basis. The following study utilized the nested case-control model to evaluate 45 potential PE risk factors of a cohort in Bogotá, Colombia, making it perhaps the most comprehensive study of its kind in Colombia. It found PE to have a statistically significant association with 7 of the 45 factors evaluated: 1) pre-gestational BMI >30 kg/m2, 2) pregnancy weight gain >12 kg, 3) previous history preeclampsia/eclampsia, 4) previous history of IUGR-SGA (Intrauterine Growth Restriction-Small for Gestational Age), 5) maternal age <20 or ≥35 years (20-34 was not associated), and 6) family history of diabetes. Finally, prenatal consumption of folic acid was found to lower the risk of PE. We recommend that, in Colombia, factors 1-6 be used to identify at risk mothers during pregnancy check-ups; that mothers be encouraged to take folic acid during pregnancy; and, that Colombia's health system and public policy address the problem of pregestational obesity.

MYT1 role in the microtia-craniofacial microsomia spectrum.

BACKGROUND: Craniofacial microsomia (CFM), also known as the oculo-auriculo-vertebral spectrum, comprises a variable phenotype with the most common features including microtia and mandibular hypoplasia on one or both sides, in addition to lateral oral clefts, epibulbar dermoids, cardiac, vertebral, and renal abnormalities. The etiology of CFM is largely unknown. The MYT1 gene has been reported as a candidate based in mutations found in three unrelated individuals. Additional patients with mutations in this gene are required to establish its causality. We present two individuals with CFM that have rare variants in MYT1 contributing to better understand the genotype and phenotype associated with mutations in this gene. METHODS/RESULTS: We conducted genetic analysis using whole-exome and -genome sequencing in 128 trios with CFM. Two novel MYT1 mutations were identified in two participants. Sanger sequencing was used to confirm these mutations. CONCLUSION: We identified two additional individuals with CFM who carry rare variants in MYT1, further supporting the presumptive role of this gene in the CFM spectrum.

The limited knowledge of placental damage due to neglected infections: ongoing problems in Latin America.

The placenta works as a selective barrier, protecting the fetus from potential infections that may affect the maternal organism during pregnancy. In this review, we will discuss several challenging infections that are common within Latin American countries and that may affect the maternal-fetal interface and pose risks to fetal development. Specifically, we will focus on emerging infectious diseases including the arboviruses, malaria, leishmaniasis, and the bacterial foodborne disease caused by Shiga toxin-producing Escherichia coli. We will also highlight some topics of interest currently being studied by research groups that comprise an international effort aimed at filling the knowledge gaps in this field. These topics address the relationship between exposure to microorganisms and placental abnormalities, congenital anomalies, and complications of pregnancy. ABBREVIATIONS: ADE: antibody-dependent enhancement; CCL2: monocyte chemoattractant protein-1; CCL3: macrophage inflammatory protein-1 α; CCL5: chemokine (C-C motif) ligand 5; CHIKV: chikungunya virus; DCL: diffuse cutaneous leishmaniasis; DENV: dengue virus; Gb3: glycolipid globotriaosylceramyde; HIF: hypoxia-inducible factor; HUS: hemolytic uremic syndrome; IFN: interferon; Ig: immunoglobulins; IL: interleukin; IUGR: intrauterine growth restriction; LCL: localized cutaneous leishmaniasis; LPS: lipopolysaccharid; MCL: mucocutaneous leishmaniasis; NO: nitric oxide; PCR: polymerase chain reaction; PGF: placental growth factor; PM: placental malaria; RIVATREM: Red Iberoamericana de Alteraciones Vasculares em transtornos del Embarazo; sVEGFR: soluble vascular endothelial growth factor receptor; STEC: shiga toxin-producing Escherichia coli; stx: shiga toxin protein; TNF: tumor necrosis factor; TOAS: T cell original antigenic sin; Var2CSA: variant surface antigen 2-CSA; VEGF: vascular endothelial growth factor; VL: visceral leishmaniasis; WHO: world health organization; YFV: yellow fever virus; ZIKV: Zika virus.

Differential Expression of IgM and IgD Discriminates Two Subpopulations of Human Circulating IgM+IgD+CD27+ B Cells That Differ Phenotypically, Functionally, and Genetically.

The origin and function of blood IgM+IgD+CD27+ B cells is controversial, and they are considered a heterogeneous population. Previous staining of circulating B cells of healthy donors with rotavirus fluorescent virus-like particles allowed us to differentiate two subsets of IgM+IgD+CD27+: IgMhi and IgMlo B cells. Here, we confirmed this finding and compared the phenotype, transcriptome, in vitro function, and Ig gene repertoire of these two subsets. Eleven markers phenotypically discriminated both subsets (CD1c, CD69, IL21R, CD27, MTG, CD45RB, CD5, CD184, CD23, BAFFR, and CD38) with the IgMhi phenotypically resembling previously reported marginal zone B cells and the IgMlo resembling both naïve and memory B cells. Transcriptomic analysis showed that both subpopulations clustered close to germinal center-experienced IgM only B cells with a Principal Component Analysis, but differed in expression of 78 genes. Moreover, IgMhi B cells expressed genes characteristic of previously reported marginal zone B cells. After stimulation with CpG and cytokines, significantly (p < 0.05) higher frequencies (62.5%) of IgMhi B cells proliferated, compared with IgMlo B cells (35.37%), and differentiated to antibody secreting cells (14.22% for IgMhi and 7.19% for IgMlo). IgMhi B cells had significantly (p < 0.0007) higher frequencies of mutations in IGHV and IGKV regions, IgMlo B cells had higher usage of IGHJ6 genes (p < 0.0001), and both subsets differed in their HCDR3 properties. IgMhi B cells shared most of their shared IGH clonotypes with IgM only memory B cells, and IgMlo B cells with IgMhi B cells. These results support the notion that differential expression of IgM and IgD discriminates two subpopulations of human circulating IgM+IgD+CD27+ B cells, with the IgMhi B cells having similarities with previously described marginal zone B cells that passed through germinal centers, and the IgMlo B cells being the least differentiated amongst the IgM+CD27+ subsets.

The umbilical cord, preeclampsia and the VEGF family.

Introduction: The VEGF family has been identified as abnormal in preeclampsia (PE). Hypertensive disorders of pregnancy (HDP) are major contributors to maternal and neonatal morbidity and mortality worldwide; likewise, umbilical cord anatomical abnormalities (UCAA) are linked to poor neonatal outcomes. Based on the relationship described between PE and UCAA and the role of the VEGF family in PE, this study explored VEGF expression in placental and UC tissued from patients with PE and with UCAA. Methods: We performed an observational, analytical study on placentas, comparing protein and mRNA expression in four groups: patients with PE, patients with UC abnormalities, patients with both, and patients with none of them. Using immunohistochemistry, we studied VEGF A, VEGF R1 (FLT1), MMP1, and PLGF. With quantitative reverse transcription polymerase chain reaction we described mRNA expression of PLGF, VEGF and sFLT1, and sFLT1/PLGF ratio. Results: Forty newborns were included. Sixty-seven percent of mothers and 45% of newborns developed no complications. Immunohistochemistry was performed on UC and placental disc paraffin-embedded tissue; in the latter, the mRNA of the VEGF family was also measured. Statistically significant differences were observed among different expressions in both HDP and UCAA groups. Interestingly, the UCAA group exhibited lower levels of sFLT1 and VEGF-A in comparison with other groups, with significant P-value for sFLT1 (P=0000.1). Conclusion: The origin of UCAA abnormalities and their relation with HDP are still unknown. VEGF family alterations could be involved in both. This study provides the first approach related to molecules linked to UCAA.

Molecular findings of Colombian patients with type VI mucopolysaccharidosis (Maroteaux-Lamy syndrome).

INTRODUCTION: Maroteaux-Lamy syndrome, or mucopolysaccharidosis (MPS) type VI, is an autosomal recessive lysosomal storage disease caused by a deficient activity of the enzyme arylsulfatase B (ARSB), required to degrade dermatan sulfate. The onset and progression of the disease vary, producing a spectrum of clinical presentation. So far, 133 mutations have been reported. The aim of this study is to determine the mutations in the ARSB gene that are responsible for this disease in Colombian patients. RESULTS: Fourteen patients with clinical manifestations and biochemical diagnosis of MPS VI were studied, including two siblings. The 8 exons of the gene were directly sequenced from patients' DNA, and 14 mutations were found. 57% of these mutations had not been previously reported (p.H111P, p.C121R, p.G446S, p.*534W, p.S334I, p.H147P, c.900T > G, and c.1531_1553del) and 43% had been previously reported (p.G144R, p.W322*, p.G302R, p.C447F, p.L128del, and c.1143-1G > C). Of the previously reported mutations, 80% have been associated with severe phenotypes and 20% with intermediate-severe phenotypes. Bioinformatic predictions indicate that the new mutations reported in this paper are also highly deleterious. CONCLUSIONS: Most of the Colombian patients in this study had private mutations.

Temperatura de almacenamiento y cantidad de ARN extraído de plasma materno / Temperature of storage and amount of RNA extracted from maternal plasma

El descubrimiento de los ácidos nucleicoscirculantes en plasma materno abrió nuevas posibilidadespara el diagnóstico prenatal no invasivo. No obstante,se desconocen los factores que afectan la concentracióndel ARN de origen feto-placentario en muestras deplasma materno. Fue investigado el efecto del tiempo dealmacenamiento (inmediatamente, 4 y 24 horas, 15 y 30 días),temperatura de almacenamiento (4ºC, -20°C y ambiente) yTrizol (con o sin) sobre la cantidad del ARN en muestrasde plasma de gestantes, antes de la semana 20 de embarazo.Se analizaron por espectrofotometría 33 muestras de ARNextraídas de plasma La temperatura afecta la concentraciónde ARN, más que el tiempo de almacenamiento y laadición de Trizol. De igual forma, la cantidad de ARN fueestadísticamente menor en muestras almacenadas a -20°C.El tiempo de almacenamiento y la presencia o ausenciade Trizol no incidió en la concentración de ARN. Enconclusión la temperatura es factor clave en la extracción deARN, donde probablemente el proceso de congelamientodescongelamientoincide negativamente en la concentraciónde ARN...

The discovery of nucleic acids in maternal plasma unlocked new possibilities for noninvasive prenataldiagnosis. However, the factors affecting the concentration of fetal RNA in maternal plasma samplesare unspecified. Here we studied the effect of storage time (15 to 30 days) and temperature (4°C, -20°Cand ambient) and of the presence of Trizol on the concentration of RNA in plasma samples taken frompregnant women before their 20th week. Thirty-three RNA samples were extracted from plasma andanalyzed by spectrophotometry. The amount of RNA was statistically lower in samples stored at -20°Cwhereas storage time and the presence or absence of Trizol did not affect RNA level. Temperature affectedthe concentration of RNA, rather than time and the addition of Trizol. In conclusion, temperature is akey factor in the extraction of RNA, and the freeze-thaw process most likely affects RNA concentrationsnegatively...

A descoberta dos ácidos nucleicos no plasmamaterno abriu novas possibilidades para o diagnóstico prénatalnão-invasivo. Desconhecem-se no entanto os fatoresque afetam a concentração do RNA de origem maternofetalnas amostras do plasma materno. Investigou-se o efeitodo tempo de armazenamento (15 a 30 dias), da temperaturade armazenamento (4°C, -20°C e ambiente), e de Trizol(com ou sem) sobre a quantidade de RNA nas amostras deplasma de gestantes, antes da vigésima semana de gravidez.33 amostras de RNA extraídas do plasma foram analisadaspor espetrofotometria. A temperatura afecta a concentraçãode RNA, mais que o tempo de armazenamento e de adiçãode Trizol. Da mesma forma, a quantidade de RNA foisignificativamente menor nas amostras armazenadas a -20°C. O tempo de armazenamento e a presença ou ausênciade Trizol não afetou os níveis de RNA. Em conclusão, atemperatura é um fator chave para a extração de RNA,onde provavelmente, o processo de congelamento edescongelamento afeta negativamente a concentração deRNA...

Asociación entre la alteración del metabolismo de la homocisteína metionina y folato, y el retardo de crecimiento intrauterino idiopático (RCIU): datos preliminares / The association between homocysteine-methionine and folate metabolism and pregnancy complicated by idiopathic intrauterine growth restriction: preliminary data

Objetivo: el objetivo general de esta investigación es hacer una aproximación para evaluar la asociación entre alteración del metabolismo de la homocisteínametionina y folato en embarazos complicados con restricción de crecimiento intrauterino (RCIU) idiopático, a través del estudio de los niveles de homocisteína pre y posparto, vitamina B12 y folato, así como las frecuencias alélicas y genotípicas de los polimorfismos genéticos de enzimas que participan en la vía metabólica de la homocisteína-metionina y folato en gestantes con embarazos complicados con RCIU idiopático y en condiciones fisiológicas en embarazo normal. Materiales y métodos: estudio piloto observacional analítico de tipo casos y controles. Se estudiaron 8 gestantes con embarazos con restricción de crecimiento intrauterino idiopático y 21 gestantes control con embarazos sin complicaciones y recién nacido sano. Se analizaron las concentraciones de folato, vitamina B12 y homocisteína en el tercer trimestre de embarazo, así como los niveles de homocisteína posparto. Se determinaron los genotipos de las gestantes para los polimorfismos MTHFR C677T, MTHFR A1298C, MTRR A66G, CBS 844ins68, CBS VNTR31pb, CBS C699T y CBS C1080T por medio de reacción en cadena de la polimerasa (PCR) y polimorfismos de longitud de los fragmentos de restricción (RFLP).Resultados: los polimorfismos MTHFR C677T y el genotipo 18/18 del polimorfismo CBS VNTR- 31pb, de manera independiente y en coexistencia, se asociaron a niveles bajos de folato. Igualmente, el genotipo 18/18 del polimorfismo CBS VNTR- 31pb, solo y cuando coexistía con el polimorfismo MTHFR C677T, se asoció con RCIU idiopático. Conclusiones: el metabolismo de la homocisteínametionina y folato es importante para el crecimiento y desarrollo del embrión-feto. El compromiso de estas rutas metabólicas se asocia a complicaciones del embarazo como RCIU idiopático. Los resultados preliminares de este estudio deben incentivar el estudio del metabolismo de la homocisteínametionina y folato en complicaciones del embarazo como la RCIU, así como en condiciones fisiológicas en el embarazo normal en nuestra población.

Objective: This work was aimed at evaluating the association between homocysteine-metionine and folate metabolism alteration and pregnancies complicated by idiopathic intrauterine growth restriction (IUGR). This was done by studying pre- and post-partum homocysteine, vitamin B12 and folate levels, as well as allele and genotype frequency for genetic polymorphisms from enzymes participating in the homocysteine-methionine and folate metabolic route in pregnant women having pregnancies complicated by idiopathic IUGR and physiological conditions during normal pregnancy. Materials and methods: This was an analytical observational (cases and controls) pilot study. Eight pregnant women suffering IUGR were studied, as well as 21 pregnant women as control whose pregnancy had no complications and healthy newborn. Folate, vitamin and B12 homocysteine concentrations as well as postpartum homocysteine levels were analyzed during the third trimester of pregnancy. The pregnant women’s genotypes were determined formethylenetetrahydrofolate reductase (MTHFR) C677T, MTHFR A1298C, methionine synthase reductase (MTRR) A66G, cystathionine betasynthase (CBS) 844ins68, CBS 31pb VNTR, CBS C699T and CBS C1080T polymorphisms by polymerase chain reaction (PCR) and restriction fragment length polymorphism (RFLP). Results: MTHFR C677T polymorphisms and the CBS 31bp VNTR 18/18 genotype (independently and in coexistence) were associated with low folate levels. The CBS 31bp VNTR 18/18 genotype alone and when coexisting with MTHFR C677T was associated with idiopathic IUGR. Conclusions: Homocysteine-methionine and folate metabolism is important for embryo-fetus growth and development. Compromise of these metabolic routes is associated with pregnancy complications such as idiopathic IUGR. This study's preliminary results should encourage studying homocysteine-methionine and folate metabolism in complications regarding pregnancy such as IUGR and in physiological conditions during normal pregnancy in our population.

Alteration of placental haemostatic mechanisms in idiopathicintrauterine growth restriction / Alteración de los mecanismos hemostáticos de la placenta en restricción de crecimiento intrauterino idiopático / Alteração dos mecanismos hemostáticos da placenta em restrição de crescimento intra-uterino idiopático

La restriccióndel crecimiento intrauterino es una complicación del embarazo con alta probabilidad de morbilidad y mortalidad perinatal, que pareceser causada por desarrollo anormal de la vasculatura placentaria. Los procesos hemostáticos son importantes para el desarrollo de laplacenta y el desequilibrio entre factores procoagulantes y anticoagulantes se ha asociado con restricción del crecimiento intrauterino.Objetivo. Evaluar el compromiso hemostático en la placenta de los embarazos complicados con restricción del crecimiento intrauterinoidiopática. Materiales y métodos. Se estudiaron cinco placentas de embarazos con restricción de crecimiento intrauterino idiopática y 19controles. Se realizó examen macroscópico e histológico, y análisis de la expresión de factor tisular y trombomodulina a nivel de ARNmpor PCR en tiempo real y proteínas por ELISA. Resultados. Se evidenció compromiso hemostático en las placentas de embarazos conrestricción de crecimiento intrauterino idiopática, siendo la trombosis de los vasos coriales el hallazgo histológico más importante. Seencontró aumento en la expresión de la proteína del factor tisular (p=0,0411) y en la razón de factor tisular/trombomodulina a nivel deARNm (p=0,0411) y proteína (p=0,0215). No hubo diferencias estadísticamente significativas entre los grupos en los niveles de ARNmde factor tisular o trombomodulina, ni de trombomodulina a nivel de proteína. Conclusión. Se presenta evidencia de alteración de losmecanismos hemostáticos de la placenta, incluyendo la expresión anormal de factor tisular y de la razón factor tisular/trombomodulina,en embarazos complicados con restricción del crecimiento intrauterino idiopática...

Intrauterine growth restriction is a complication of pregnancy with a high probability of perinatal morbidity and mortality. It appears tobe caused by abnormal development of placental vasculature. Haemostatic processes are important for the development of the placenta,and an imbalance between procoagulant and anticoagulant factors has been associated with risk of intrauterine growth restriction.Objective. To evaluate coagulation abnormalities in placenta of pregnancies complicated with idiopathic intrauterine growth restriction.Materials and methods. Five placentas from pregnancies with idiopathic intrauterine growth restriction were compared to 19 controls.We performed gross and histological examination of the placenta. Analysis was made of both mRNA expression by real-time PCRand protein by ELISA of tissue factor and thrombomodulin in placental tissue. Results. Results based on histological evaluation wereconsistent with an increased prothrombotic state in placentas from pregnancies with idiopathic intrauterine growth restriction, andthrombosis of chorionic vessels was the most important finding. The study showed an increased expression of tissue factor protein(p=0.0411) and an increase in the ratio of tissue factor/thrombomodulin mRNA (p=0.0411) and protein (p=0.0215) in placentas frompregnancies with idiopathic intrauterine growth restriction. There were no statistically significant differences neither between cases andcontrols in the mRNA levels of tissue factor or thrombomodulin nor at the protein level of thrombomodulin. Conclusion. Evidence ofalteration of local haemostatic mechanisms at the level of the placenta, including abnormal expression of tissue factor and tissue factor/thrombomodulin ratio, in pregnancies that occur with idiopathic intrauterine growth restriction is presented...

A restrição do crescimentointra-uterino é uma complicação da gravidez com alta probabilidade de morbidade e mortalidade perinatal, que parece ser causada pelodesenvolvimento anormal da vasculatura placentária. Os processos hemostáticos são importantes para o desenvolvimento da placenta,e o desequilíbrio entre fatores pró-coagulantes e anticoagulantes têm sido associadas com a restrição de crescimento intra-uterino.Objetivo. Avaliar o compromisso hemostático na placenta com gestações complicadas com restrição de crescimento intra-uterinoidiopático. Materiais e métodos. Foram estudadas cinco placentas de gestações com restrição de crescimento intra-uterino idiopáticoe 19 controles. Foi realizada uma análise macroscópica e histológica e análise da expressão do factor tecidual e trombomodulina emARNm por PCR em tempo real e de proteína pelo método de ELISA. Resultados. Foi evidente o compromisso hemostático nas placentasde gestações com restrição de crescimento intra-uterino idiopático; a trombose dos vasos coriônicos é o descobrimento histológico maisimportante. Aumentaram a expressão de proteína do fator tecidual (p= 0,0411) e a proporção do fator tecidual/ trombomodulina aonível de ARNm (p= 0,0411) e de proteína (p= 0,0215). Não houve diferenças estatisticamente significativas entre os grupos nos níveisde ARNm do fator tecidual ou trombomodulina, nem de trombomodulina ao nível de proteína. Conclusão. Se apresenta evidência dealteração dos mecanismos hemostáticos da placenta, incluindo a expressão anormal de fator tecidual e da proporção do fator tecidual/trombomodulina, em gestações complicadas com restrição de crescimento intra-uterino idiopático...

Identification of messenger RNA of fetoplacental source in maternal plasma of women with normal pregnancies and pregnancies with intrauterine growth restriction / Identificacion de RNA mensajero de origen fetoplacentario en plasma materno de mujeres con embarazos normales y gestantes con restriccion de crecimiento intrauterino

Objective: to quantify placenta-specific RNA in plasma of women carrying foetuses with intrauterine growth restriction and pregnant women with normal pregnancies. Materials and methods: 8 pregnant women with foetuses with intrauterine growth restriction were studied as well as 18 women with uncomplicated pregnancies in the third pregnancy trimester. Total free RNA was quantified in maternal plasma by spectrophotometry and the gene expression of hPL (Human Placental Lactogen) at the messenger RNA level through technical Real Time-Chain Reaction Polymerase. Results: plasma RNA of fetoplacental origin was successfully detected in 100% of pregnant women. There were no statistically significant differences between the values of total RNA extracted from plasma (p = 0.5975) nor in the messenger RNA expression of hPL gene (p = 0.5785) between cases and controls. Conclusion: messenger RNA of fetoplacental origin can be detected in maternal plasma during pregnancy.(AU)Objective: to quantify placenta-specific RNA in plasma of women carrying foetuses with intrauterine growth restriction and pregnant women with normal pregnancies. Materials and methods: 8 pregnant women with foetuses with intrauterine growth restriction were studied as well as 18 women with uncomplicated pregnancies in the third pregnancy trimester. Total free RNA was quantified in maternal plasma by spectrophotometry and the gene expression of hPL (Human Placental Lactogen) at the messenger RNA level through technical Real Time-Chain Reaction Polymerase.Results: plasma RNA of fetoplacental origin was successfully detected in 100% of pregnant women. There were no statistically significant differences between the values of total RNA extracted from plasma (p = 0.5975) nor in the messenger RNA expression of hPL gene (p = 0.5785) between cases and controls.Conclusion: messenger RNA of fetoplacental origin can be detected in maternal plasma during pregnancy

Objetivo: cuantificar RNA específico de placenta en el plasma de mujeres con embarazos con fetos con Restricción de Crecimiento Intrauterino y gestantes con embarazos normales. Materiales y métodos: se estudiaron 8 mujeres con embarazos con fetos con Restricción de Crecimiento Intrauterino y 18 mujeres con embarazos sin complicaciones, en el tercer trimestre de embarazo. Se cuantificó el RNA total libre en plasma materno por espectrofotometría y la expresión del gen hPL (Lactógeno Placentario Humano) a nivel de RNA mensajero por medio de la técnica Reacción en Cadena de la Polimerasa en Tiempo Real. Resultados: se logró detectar RNA en plasma de origen fetoplacentario en el 100% de las gestantes. No se encontraron diferencias estadísticamente significativas entre los valores de RNA total extraído de plasma (p=0,5975) ni en la expresión del RNA mensajero del gen hPL (p=0,5785) entre casos y controles. Conclusión: es posible detectar RNA mensajero de origen fetoplacentario en plasma materno durante el embarazo.

Epigenética: definición, bases moleculares e implicaciones en la salud y en la evolución humana / Epigenetics: definition, molecular bases and implications in human health and evolution / Epigenética: definição, bases moleculares e implicações na saúde e na evolução humana

La Epigenética se refiere a los cambios heredables en el ADN e histonas que no implican altera ciones en la secuencia de nucleótidos y modifican la estructura y condensación de la cromatina por lo que afectan la expresión génica y el fenotipo. Las modificaciones epigenéticas son metilación del ADN y modificaciones de histonas. Objetivo: hacer una revisión de la literatura sobre e concepto de epigenética y su impacto en la salud. Materiales y métodos: se realizó una revisión de la bibliografía sobre el concepto de epigenética, sus bases biológicas, el impacto sobre la salud y la enfermedad y su relación con la evolución. Resultados: los mecanismos epigenéticos ha cobrado cada vez más importancia debido a la creciente asociación con enfermedades compleja y comunes, así como por su impacto en la salud de generaciones futuras y en la evolución humana. Conclusiones: la Epigenética tiene un claro impacto en la salud del individuo, en la de su descendencia y en la evolución de la especie humana.

Epigenetics refers to inheritable changes in DNA and histones that do not involve changes in the sequence of nucleotides and that modifies structure and chromatin condensation, thus affecting gene expression and phenotype. Epigenetic modifications are DNA methylation and histone modifications. Objective: A review of the literature on the concept of Epigenetics and its impact on health. Materials and methods: A review of the literature was performed on the concept of epigenetics, its biological basis, the impact on health and disease and its relation to evolution. Results: Epigenetic mechanisms have become increasingly important because of the growing association with common complex diseases as well as its impact on health of future generations and in human evolution. Conclusions: Epigenetics has a clear impact on the health of individuals in their offspring and with the evolution of the human species.

A Epigenética refere-se às mudanças hereditárias no ADN e histonas que não implicam alterações nas sequencia de nucleotídeos e modificam a estrutura e condensação da cromatina, pelo que afetam a expressão gênica e o fenótipo. As modificações epigenéticas são metilação do ADN e modificações de histonas. Objetivo: fazer uma revisão da literatura sobre o conceito de epigenética e seu impacto na saúde. Materiais e métodos: realizou-se uma revisão da bibliografia sobre o conceito de epigenética, suas bases biológicas, o impacto sobre a saúde e a doença e sua relação com a evolução. Resultados: os mecanismos epigenéticos têm adquirido cada vez mais importância devido à crescente associação com doenças complexas e comunes, assim como por seu impacto na saúde de gerações futuras e na evolução humana. Conclusões: a Epigenética tem um impacto evidente na saúde do individuo, na sua descendência e na evolução da espécie humana.

Identification of messenger RNA of fetoplacental source in maternal plasma of women with normal pregnancies and pregnancies with intrauterine growth restriction.

OBJECTIVE: to quantify placenta-specific RNA in plasma of women carrying foetuses with intrauterine growth restriction and pregnant women with normal pregnancies. METHODS: 8 pregnant women with foetuses with intrauterine growth restriction were studied as well as 18 women with uncomplicated pregnancies in the third pregnancy trimester. Total free RNA was quantified in maternal plasma by spectrophotometry and the gene expression of hPL (Human Placental Lactogen) at the messenger RNA level through technical Real Time-Chain Reaction Polymerase. RESULTS: plasma RNA of fetoplacental origin was successfully detected in 100% of pregnant women. There were no statistically significant differences between the values of total RNA extracted from plasma (p= 0.5975) nor in the messenger RNA expression of hPL gene (p= 0.5785) between cases and controls. CONCLUSION: messenger RNA of fetoplacental origin can be detected in maternal plasma during pregnancy.

OBJETIVO: cuantificar RNA específico de placenta en el plasma de mujeres con embarazos con fetos con Restricción de Crecimiento Intrauterino y gestantes con embarazos normales. MÉTODOS: se estudiaron 8 mujeres con embarazos con fetos con Restricción de Crecimiento Intrauterino y 18 mujeres con embarazos sin complicaciones, en el tercer trimestre de embarazo. Se cuantificó el RNA total libre en plasma materno por espectrofotometría y la expresión del gen hPL (Lactógeno Placentario Humano) a nivel de RNA mensajero por medio de la técnica Reacción en Cadena de la Polimerasa en Tiempo Real. RESULTADOS: se logró detectar RNA en plasma de origen fetoplacentario en el 100% de las gestantes. No se encontraron diferencias estadísticamente significativas entre los valores de RNA total extraído de plasma (p= 0.5975) ni en la expresión del RNA mensajero del gen hPL (p= 0.5785) entre casos y controles. CONCLUSIÓN: es posible detectar RNA mensajero de origen fetoplacentario en plasma materno durante el embarazo.